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ABSTRACT The biological mediator hydrogen sulﬁde (H2S) is produced by bacteria
and has been shown to be cytoprotective against oxidative stress and to increase
the sensitivity of various bacteria to a range of antibiotic drugs. Here we evaluated
whether bacterial H2S provides resistance against the immune response, using two
bacterial species that are common sources of nosocomial infections, Escherichia coli
and Staphylococcus aureus. Elevations in H2S levels increased the resistance of both
species to immune-mediated killing. Clearances of infections with wild-type and ge-
netically H2S-deﬁcient E. coli and S. aureus were compared in vitro and in mouse
models of abdominal sepsis and burn wound infection. Also, inhibitors of H2S-
producing enzymes were used to assess bacterial killing by leukocytes. We found
that inhibition of bacterial H2S production can increase the susceptibility of both
bacterial species to rapid killing by immune cells and can improve bacterial clear-
ance after severe burn, an injury that increases susceptibility to opportunistic infec-
tions. These ﬁndings support the role of H2S as a bacterial defense mechanism
against the host response and implicate bacterial H2S inhibition as a potential thera-
peutic intervention in the prevention or treatment of infections.
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Hydrogen sulﬁde (H2S) is a gaseous biological mediator that regulates importantfunctions in the nervous, cardiovascular, immune, and gastrointestinal systems. The
importance of H2S as an endogenous mediator in mammalian systems is highlighted by
discoveries that disruptions in H2S homeostasis are associated with a wide range of disease
states, including cardiovascular diseases, diabetes, burn injury, ischemia-reperfusion, and
cancer (1). In mammalian cells, H2S is produced by three enzymes: cystathionine -synthase
(CBS), cystathionine -lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST) (1, 2).
Bacteria can also produce H2S via orthologous enzymes (3). While bacterial H2S
production was long perceived primarily as a metabolic by-product, recent studies have
implicated H2S as an important signaling molecule in bacteria. H2S can protect bacteria
from antibiotic-induced damage, at least in part by sequestering free iron to prevent
the Fenton reaction that generates toxic hydroxyl radicals (3, 4). Additionally, H2S can
regulate intracellular cysteine, which can be toxic at high levels (4). Recently, it was
demonstrated that H2S, and downstream reactive sulfur species, can regulate the
expression of some bacterial virulence genes through S-sulfhydration of the proteome
(5). Given the importance of reactive oxygen species (ROS) in antimicrobial immune
responses, especially innate responses (6), we have now evaluated whether bacterial
H2S protects bacteria from the host immune response by manipulating H2S levels in
bacteria without modulation of host H2S. The ﬁndings in this report support the role of
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H2S as a bacterial defense mechanism and implicate bacterial H2S inhibition as a
potential therapeutic intervention for the treatment or prevention of infections.
RESULTS
Because manipulation of host H2S production could have potential effects on the
immune response to infection, experiments were designed to speciﬁcally manipulate
bacterial, but not host, H2S levels. To determine if pharmacological donation of H2S can
increase the resistance of bacteria to the immune response, Escherichia coli and
Staphylococcus aureus were cultured in the presence or absence of a slow-release H2S
donor, GYY4137 (7). GYY4137 is an organic small molecule that slowly decomposes to
release low levels of H2S over a prolonged period of time. Its use as a low-level H2S
generator in biological systems, both mammalian and nonmammalian, has been well
characterized (8, 9). To prevent any direct effects of GYY4137 on host cells, bacteria
were preincubated with the H2S donor, which was removed prior to inoculation of the
mouse leukocyte cultures. H2S donation to E. coli concentration-dependently reduced
leukocyte-mediated clearance of E. coli in vitro (P 0.05) (Fig. 1). Bacterial clearance was
completely prevented at the highest concentrations of GYY4137 tested (0.3 and 1 mM),
allowing bacterial growth in the presence of leukocytes, suggesting that H2S can
protect E. coli from immune-mediated killing. Similarly, at concentrations of 0.3 and
1 mM, GYY4137 signiﬁcantly reduced and prevented rapid killing of S. aureus in vitro
(P 0.05) (Fig. 1). This was not due to effects of GYY4137 on bacterial proliferation
rates, as bacterial counts were similar in the corresponding control cultures lacking
leukocytes (not shown).
Since pharmacological donation of H2S increased the resistance of both E. coli and
S. aureus to killing by leukocytes, we attempted to pharmacologically inhibit H2S
production in these two bacterial species. E. coli lacks homologues for the mammalian
H2S-producing enzymes CBS and CSE but expresses the 3-MST homologue that is
encoded by the sseA gene (3). Because there are currently no inhibitors available that
are speciﬁc for bacterial 3MST, an inhibitor of mouse 3-MST (10, 11) was preincubated
with E. coli, and removed, prior to inoculation of leukocytes. E. coli production of H2S,
FIG 1 E. coli and S. aureus were cultured with increasing concentrations of up to 1 mM GYY4137 prior
to inoculation of mouse leukocyte cultures. Graphs show percentages of inoculum CFU killed after
coculture with leukocytes. *, signiﬁcantly different from 0 mM (n  4 to 5 replicates per group).
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detected by reaction with lead acetate, was decreased but not completely inhibited in
the presence of increasing concentrations of the 3-MST inhibitor. The ability of this
inhibitor to inhibit bacterial 3MST was conﬁrmed, as the activity of puriﬁed bacterial
3MST was decreased but not completely inhibited in the presence of increasing
concentrations of the 3-MST inhibitor (Fig. 2A). In vitro clearance of E. coli was signiﬁ-
cantly increased in the presence of the 3-MST inhibitor, in a dose-dependent manner
(P 0.05) (Fig. 2A).
S. aureus lacks 3MST but expresses CBS and CSE homologues (3). It was observed
that the level of H2S production by S. aureus was markedly lower than that of E. coli and
nearly undetectable by reaction with lead. However, supplementation of cultures with
200 M cysteine, a substrate for both CBS and CSE, increased H2S production to
detectable levels (Fig. 2B). Because bacterium-speciﬁc CBS and CSE inhibitors are not
available, commonly used inhibitors of the mammalian homologues were used in an
attempt to decrease H2S production by S. aureus. Amino-oxyacetic acid (AOAA) is an
inhibitor of human CBS that also has some inhibitory activity against human CSE.
Propargylglycine (PAG) inhibits human CSE but not CBS (12). These inhibitors were
previously demonstrated to reduce H2S production by S. aureus (3). S. aureus bacteria
FIG 2 (A) Image showing brown lead sulﬁde staining produced by reaction of lead acetate with H2S
produced by E. coli cultured with or without the 3-MST inhibitor. The graph on the left shows the activity
of bacterial 3MST in the presence of increasing concentrations of the 3-MST inhibitor, expressed as a
percentage of 3MST activity in the control (no inhibitor) (n  3 replicates/group). The graph on the right
shows in vitro elimination of E. coli by leukocytes after 45 min. WT E. coli bacteria were cultured in the
presence of the 3-MST inhibitor prior to inoculation of leukocytes. *, signiﬁcantly different from 0 M; #,
signiﬁcantly different from 1 M (n 5/group). (B) Brown lead sulﬁde stain produced by reaction of lead
acetate with H2S from S. aureus cultured with or without increasing concentrations of AOAA or PAG, in
the presence (Cys) or absence (Cys) of 200 M cysteine supplementation. Graphs show in vitro
elimination of S. aureus by leukocytes after 60 min. WT S. aureus bacteria were cultured with inhibitors
prior to inoculation of leukocytes. *, signiﬁcantly different from 0 mM; #, signiﬁcantly different from 3mM
(n  5/group).
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were preincubated with either AOAA or PAG, which was subsequently removed prior
to inoculation of leukocytes. As shown in Fig. 2B, AOAA effectively decreased H2S
production in S. aureus cultures. AOAA (at a concentration of 1 mM) increased the
clearance of S. aureus by leukocytes (P 0.05) (Fig. 2B). Similarly, H2S production by S.
aureus was inhibited by PAG in a dose-dependent manner, as was in vitro clearance of
S. aureus by leukocytes (P 0.05) (Fig. 2B).
Because the 3-MST, CBS, and CSE inhibitors used here would inhibit the activity of
the respective enzymes in host (mouse) cells, which could potentially affect the host
response to infection, we were unable to include the inhibitors during the in vitro
bacterial killing assays; therefore, rapid bacterial clearance was assessed immediately
after the removal of the inhibitors from bacteria and within a short time frame, during
which bacterial proliferation was negligible. Additionally, we were unable to treat
infected mice to determine the therapeutic potential of bacterial 3MST, CBS, or CSE
inhibition for clearance of E. coli or S. aureus infections in vivo, as continued treatment
with inhibitors would be required while bacteria replicate and disseminate in vivo,
making it difﬁcult to distinguish effects caused by bacterial versus host H2S inhibition.
Therefore, bacteria that are genetically deﬁcient in speciﬁc H2S-synthesizing enzymes
were utilized for further studies.
To establish a role of bacterial 3MST in E. coli defense against the immune response,
wild-type (WT) E. coli and sseA-deﬁcient E. coli strains were utilized. As shown in Fig. 3A,
H2S production by 3MST-deﬁcient E. coli (ΔsseA) is negligible compared to that by WT
E. coli. Additionally, the level of rapid clearance of E. coli by leukocytes in vitro was
signiﬁcantly higher in cultures inoculated with the ΔsseA strain (45% bacterial clear-
ance) than in those inoculated with the WT (12% clearance; P 0.05) (Fig. 3A). Levels
of bacterial proliferation were negligible during the bacterial clearance assay and were
similar between WT E. coli and the ΔsseA strain. The susceptibility of sseA-deﬁcient E. coli
bacteria was reversed when they were preincubated in the presence of the H2S donor
(P 0.05) (Fig. 3B), and bacterial clearance was completely prevented at higher
GYY4137 concentrations (0.3 and 1 mM).
Signiﬁcant differences in the clearance of opsonized bacteria by total leukocytes
were detected within an hour, suggesting H2S-mediated protection from early innate
immune responses. To further deﬁne a role of 3MST in E. coli defense against phago-
cytic killing, the macrophage-like RAW 264.7 cell line was used. The 3MST-deﬁcient E.
coli bacteria were killed more rapidly than WT E. coli bacteria. Speciﬁcally, in cultures
inoculated with WT E. coli, 38% of the bacteria were killed by 1 h, and 64% were killed
by 2 h (Fig. 3C), whereas 68% of ΔsseA strain bacteria were killed by 1 h, and 84% were
killed by 2 h. To compare resistances of the two strains to intracellular killing, intracel-
lular viability was measured by a gentamicin protection assay. At the start of the assay
(time zero), which was 1.5 h following inoculation of macrophage cultures with E. coli,
there were signiﬁcantly more viable intracellular wild-type E. coli bacteria than ΔsseA
strain bacteria, and the numbers of viable intracellular WT E. coli bacteria remained
steady throughout the assay, whereas numbers of viable intracellular E. coli ΔsseA
bacteria consistently decreased and were signiﬁcantly lower at all time points (P 0.05)
(Fig. 3C).
To determine if deﬁciency in H2S-producing enzymes similarly increases suscepti-
bility of S. aureus to immune responses, clearance of wild-type and cbs- and cse-
deﬁcient S. aureus in vitro was measured when levels of proliferation were negligible
and similar between the two strains (Fig. 4A). As observed previously, the level of S.
aureus production of H2S was low in the absence of cysteine supplementation. Figure
4A shows a very faint precipitate with WT S. aureus that was not observed with the Δcbs
Δcse strain. Supplementation of cultures with cysteine increased H2S production to
detectable levels, with substantially lower levels being produced by cbs- and cse-
deﬁcient S. aureus. The rate of bacterial clearance was signiﬁcantly higher in cultures
inoculated with the Δcbs Δcse strain (71%) than in cultures inoculated with WT S. aureus
(23% elimination; P 0.05) (Fig. 4A). The susceptibility of Δcbs Δcse strain bacteria to
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leukocytes was reversed in the presence of increasing concentrations of the H2S donor
GYY4137 (P 0.05) (Fig. 4B).
To determine if H2S deﬁciency affects bacterial clearance in vivo, mice were infected
intraperitoneally (i.p.) with WT or H2S-deﬁcient bacteria. Bacterial burden and systemic
levels of interleukin-6 (IL-6), a marker of systemic inﬂammation and an indicator of poor
outcomes during sepsis in mice and humans (13, 14), were measured 16 h later. When
mice were inoculated i.p. with equal numbers of WT or 3MST-deﬁcient E. coli bacteria,
all mice infected with WT E. coli developed bacteremia, with a mean bacterial burden
of 1.5 103 CFU/ml in the blood, whereas only 1 of 5 mice inoculated with the ΔsseA
strain had a positive blood culture, which was negligible (200 CFU/ml). The bacterial
burden in the spleen was similarly and signiﬁcantly lower in ΔsseA strain-infected mice
(3.4 105 CFU/g in the ΔsseA strain group versus 2.5 107 CFU/g in the WT E. coli
FIG 3 (A) Images showing brown lead sulﬁde staining produced by reaction of lead acetate with H2S produced by
bacterial cultures. WT, wild-type E. coli; ΔsseA, sseA-deﬁcient E. coli. (Left) Bacterial elimination by leukocytes after
45 min in vitro. *, signiﬁcantly different from the WT (n 6/group). (Right) Densities of E. coliWT and ΔsseA bacteria
in liquid cultures over 5 h, measured by the OD600, and viability in cell culture medium, measured as CFU per
milliliter (n  3/group). (B) E. coli ΔsseA bacteria were cultured in the presence of GYY4137 prior to inoculation of
mouse leukocytes. The graph shows bacterial elimination after 45 min of coculture. *, signiﬁcantly different from
0 mM (n  4 per group). (C, left) Total killing of E. coli bacteria by RAW 264.7 macrophages after 1 and 2 h in vitro.
*, signiﬁcantly different from all other groups (n  7/group). (Right) Levels (CFU per milliliter) of viable intracellular
E. coli bacteria recovered from RAW 264.7 cells. *, signiﬁcantly different from the ΔsseA group at the corresponding
time point (n  6/group and time point).
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group; P 0.05) (Fig. 5A). Additionally, systemic levels of IL-6 were lower in ΔsseA
strain-infected mice (372 17.9 pg/ml) than in those infected with WT E. coli
(1,480 175 pg/ml; P 0.05). This was not caused by differences in basic growth
rates between the two strains, as levels of proliferation over 16 h (time frame of the
in vivo infection) were similar between E. coli WT and ΔsseA bacteria (Fig. 5A).
Similarly, when mice were given an i.p. inoculation with equal numbers of S. aureus
WT and Δcbs Δcse bacteria, mean bacterial counts in the spleen 16 h later were
signiﬁcantly lower in Δcbs Δcse strain-infected mice (4.4 106 CFU/g) than in mice
infected with WT S. aureus (4.3 107 CFU/g; P 0.05) (Fig. 5B). Additionally, there
was a signiﬁcant reduction in the level of systemic inﬂammation marker IL-6 in Δcbs
Δcse strain-infected mice compared to WT-infected mice (2,950 1,222 pg/ml for
the wild type; 170.0 6.401 pg/ml for the Δcbs Δcse strain; P 0.05) (Fig. 5B).
Bacterial growth rates were nearly identical between the two strains within the ﬁrst
8 h, after which time growth of the Δcbs Δcse strain was slightly slower than that
of the WT strain (Fig. 5B).
To determine if bacterial H2S deﬁciency has therapeutic potential under conditions
in which immune responses to infection are deﬁcient, bacterial clearance was measured
in mouse models of burn injury-associated infections. Burn patients are susceptible to
life-threatening infections, due largely to burn-induced alterations in immune function
that decrease patient defense against opportunistic microorganisms, and similar im-
munological perturbations occur in mice after burns. First, burn-injured mice were
infected i.p. with E. coli as a model of burn-associated bacterial peritonitis. Peritonitis
frequently develops into abdominal sepsis, and E. coli is a common contributor (15). As
FIG 4 (A) Images showing brown lead sulﬁde staining produced by reaction of lead acetate with H2S produced by
bacteria grown with or without cysteine (Cys) (200 M) supplementation. WT, wild-type S. aureus; Δcbs Δcse, S.
aureus lacking the cbs and cse genes. The graph on the left shows bacterial clearance by leukocytes after 60 min in
vitro. *, signiﬁcantly different from the WT (n  6/group). The graphs on the right show densities of S. aureus WT
and Δcbs Δcse bacteria in liquid cultures over 5 h, measured by the OD600, and viability in cell culture medium,
measured as CFU per milliliter (n  3/group). (B) S. aureus Δcbs Δcse bacteria were cultured in the presence of
GYY4137 prior to inoculation of mouse leukocytes. The graph shows the percentage of the inoculum cleared after
coculture with leukocytes. *, signiﬁcantly different from 0 and 0.1 mM (n  5 per group).
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shown in Fig. 5C, the bacterial burden was signiﬁcantly lower in burned mice infected
with the ΔsseA strain (1.5 107 CFU/g) than in mice infected with WT E. coli (1.2 109
CFU/g) (P 0.05). Next, the effects of bacterial H2S deﬁciency on clearance of S. aureus
burn wound infection were examined. Wound infections are a common contributor
to sepsis in burn patients, and methicillin-resistant S. aureus (MRSA) is a common
early colonizer of burn wounds (16, 17). Burn wounds were inoculated with S. aureus
WT or Δcbs Δcse bacteria, and bacterial growth within the wound and dissemination
FIG 5 (A, left) Bar graphs showing bacterial counts in spleen and IL-6 levels in plasma 16 h after i.p. injection
of mice with 1 108 CFU E. coli. *, signiﬁcantly different from the WT (n  5 mice/group). (Right) Densities
of E. coli WT and ΔsseA bacteria in liquid cultures, measured by the OD600 over 16 h. (B, left) Bar graphs
showing bacterial counts in spleens and plasma IL-6 levels in mice 16 h after i.p. injection of 5 108 CFU
S. aureus. *, signiﬁcantly different from the WT (n 5/group). (Right) Densities of S. aureusWT and Δcbs Δcse
bacteria in liquid cultures, measured by the OD600 over 16 h. (C, left) Graph showing bacterial counts in
spleens of burned mice 16 h after i.p. injection of mice with 1 108 CFU E. coli. *, signiﬁcantly different from
the WT (n  5 mice/group). (Right) Graphs showing bacterial counts in burn wounds and spleens of mice
24 h after inoculation of wounds with 1 106 CFU S. aureus. *, signiﬁcantly different from the WT (n  3
to 4/group).
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were measured. At 24 h postinoculation, there were signiﬁcantly fewer bacteria in
the wounds of mice inoculated with the Δcbs Δcse strain (7.9 104 CFU/g) than in
mice inoculated with WT S. aureus (9.6 106 CFU/g) (P 0.05) (Fig. 5C). Similarly,
the bacterial burden in the spleen was lower in Δcbs Δcse strain-infected mice than
in those infected with WT S. aureus (1.4 103 CFU/g with the Δcbs Δcse strain;
1.7 104 CFU/g with the WT).
DISCUSSION
The observations that elevations in H2S levels make both E. coli and S. aureus
resistant to leukocyte-mediated killing and that decreases in bacterial H2S levels
increase the susceptibility of these bacteria to killing by the host both in vivo and in
vitro demonstrate that H2S can provide some protection of bacteria against early
immune responses. This is further supported by the fact that E. coli and S. aureus utilize
different enzymatic pathways for the synthesis of H2S, and a loss of the respective
enzyme activities in each bacterial species induces susceptibility to the host immune
response. Our data show that the effects of bacterial H2S are not likely due to effects
on bacterial proliferation, as levels of growth of wild-type and H2S-deﬁcient E. coli and
S. aureus were similar during the lag and exponential phases (Fig. 3 to 5). While speciﬁc
mechanisms of protection are not known, previous reports provide some insight into
possible bacterial defenses that could be regulated by H2S. H2S can prevent oxidative
damage to bacteria through stimulation of superoxide dismutase and catalase activi-
ties, sequestration of free iron to prevent hydroxyl radical production via the Fenton
reaction, and control of intracellular cysteine, which can stimulate hydroxyl radical
production and inhibit electron transport at high levels (3, 4, 18). Additionally, hydro-
gen sulﬁde can inhibit the activity of myeloperoxidase (19). The increased susceptibility
of opsonized H2S-deﬁcient bacteria to rapid killing by total leukocytes in vitro suggests
that bacterial H2S protects against rapid innate responses, which could include extra-
cellular reactive oxygen species (ROS) and reactive nitrogen species (RNS) and intra-
cellular ROS/RNS in phagosomes. This is supported by the susceptibility of H2S-deﬁcient
E. coli to intracellular killing by macrophages, which is largely mediated by the
generation of toxic radicals. However, the results from this study show signiﬁcantly
improved clearance of H2S-deﬁcient bacteria by total splenic leukocytes, of which the
percentage of phagocytic cells is relatively low in the mouse. Therefore, there are likely
other immune responses that may be resisted by bacterial H2S, and further studies are
needed to determine which speciﬁc immunological mechanisms can be resisted or
avoided in the presence of bacterial H2S. Therefore, although this study found that
bacterial H2S can protect bacteria from the host immune response, it is limited by a lack
of identiﬁed mechanisms.
While nearly all bacterial species express orthologues of at least one mammalian
H2S-synthesizing enzyme (3), the relative importance of H2S as a bacterial defense
mechanism across a wide range of bacteria may vary and remains to be determined.
Baseline levels of H2S production vary between bacterial species, as demonstrated here
(S. aureus  E. coli), and may further vary when bacteria are stressed by the host
immune response. Additionally, the presence of different pathogenic and virulence
factors that can affect the host response and bacterial infectivity may inﬂuence the
relative importance of H2S in bacterial self-defense. Nonetheless, as the two bacterial
species used here differ not only in their pathogenicity and elicitation of speciﬁc host
responses but also in their utilization of H2S-producing enzymes, the results presented
here implicate H2S as a potentially global bacterial defense mechanism against the host
immune response that may be targeted in the development of novel antimicrobial
agents. Inhibition of bacterial H2S may be a particularly beneﬁcial approach to antimi-
crobial therapy in patients with inadequate immune functions, such as severe-burn
patients. Burn injury induces impairments in both innate and acquired immune func-
tions that can decrease the ability of the patient to respond effectively to an infection
(20–22). The ﬁnding that both E. coli peritonitis and S. aureus burn wound infections are
better controlled in burned mice when the respective bacteria are H2S deﬁcient
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suggests that bacterial H2S inhibition may have potential as a prophylactic measure to
prevent infections in high-risk patients.
While the magnitude of the effects of H2S deﬁciency on bacterial clearance suggests
that H2S inhibition alone would not be sufﬁcient to treat an ongoing infection, it may
be useful as an adjunct to increase the efﬁcacy of antibiotics. H2S can also provide
resistance for many bacterial species against a broad range of antibiotics (3). Therefore,
bacterial H2S is implicated as a potential therapeutic target to enhance bacterial killing by
both immune cells and antibiotics. However, the differential dependence of various bac-
terial species on the different H2S-producing enzymes during the response to infection or
antibiotic-induced stress mandates that the H2S-inhibitory strategy be matched to the
particulars of the H2S-producing system in the respective bacterial strain(s). For example,
the greater effect of PAG (than of AOAA) on the clearance of S. aureus (Fig. 2) suggests that
cse activity may be more important for defense of S. aureus against the early immune
response. Alternatively, combined treatment with multiple inhibitors that target all 3
primary bacterial H2S-synthesizing enzymes may be more appropriate as a global treat-
ment to be used prophylactically in high-risk patients or in conjunction with antibiotics.
Unfortunately, the ability to further advance the current studies is restricted by a lack of
inhibitors with speciﬁcity for the bacterial enzymes. While the mammalian enzyme inhib-
itors used here (Fig. 2) show some effects on bacterial H2S production and susceptibility to
leukocyte-mediated killing in vitro, the potency of each inhibitor against the mammalian
homologues is higher (10). In mammals, H2S is important for a wide range of important
biological functions, including cellular bioenergetics and cardiovascular and neuronal
functions (1). Additionally, H2S has been reported to have both pro- and anti-inﬂammatory
effects (23, 24). Therefore, these inhibitors are not suitable for the treatment of bacterial
infections due to their inhibitory effects on host enzymes. Given the apparent role of
bacterial H2S in defense against both the immune response and antibiotics, there is a need
for the development of inhibitors that are speciﬁc for bacterial H2S-synthesizing enzymes
to be considered novel antimicrobial agents.
MATERIALS AND METHODS
Bacterial strains. Two different wild-type species (and their H2S mutant counterparts) that differ in
their utilization of H2S-producing enzymes were used. E. coli (MG1655) is an avirulent Gram-negative rod
that primarily utilizes 3-MST, encoded by sseA, for H2S production. To generate 3MST-deﬁcient E. coli
(ΔsseA), the sseA gene was excised from E. coli (3) by Int/Xis site-speciﬁc recombination, using the
pMWts-Int/Xis-helper plasmid as described previously (25) and sseA-speciﬁc primer sequences (3). The
S. aureus strain (USA300) is Gram positive and methicillin resistant and lacks 3MST but carries the cbs-cse
operon (3). S. aureus wild-type and Δcbs Δcse strains were obtained from the Nebraska Transposon
Mutants Library. Bacteria were grown in Luria-Bertani (LB) broth with shaking (200 rpm) at 37°C, and CFU
were determined by plating diluted aliquots on LB agar plates. Growth rate curves were established by
measuring the optical density at 600 nm (OD600) over time. Culture medium for the Δcbs Δcse strain was
supplemented with 10 g/ml erythromycin. Bacterial growth and viability in cell culture medium (RPMI
1640 with 10% fetal bovine serum [FBS]) were measured by plating serial dilutions of cultures over time
for determination of CFU per milliliter.
Animals.Male BALB/c mice (10 to 12 weeks of age; Envigo) were housed in a biosafety level 2 (BSL-2)
animal facility under the supervision of the University of Texas Medical Branch (UTMB) Animal Resource
Center and veterinarians, which is accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care. Animal care and all procedures were compliant with NIH guidelines for the care
and use of experimental animals and were approved by the University of Texas Medical Branch
Institutional Animal Care and Use Committee. Some mice received a full-thickness scald burn to
approximately 35% of the body surface area, as described previously (13), under deep anesthesia (2%
isoﬂurane) with preemptive analgesia (0.1 mg/kg of body weight buprenorphine). Fluid resuscitation
(2 ml lactated Ringer’s solution, i.p.) was administered after injury.
Bacterial clearance assays. (i) In vitro. For in vitro bacterial elimination assays, total leukocytes were
isolated from the spleens of male BALB/c mice as described previously (26). Bacteria were opsonized by
incubation with 5% mouse serum (Sigma-Aldrich) at room temperature for 15 min and then incubated
at 37°C with leukocytes in RPMI 1640 supplemented with 10% FBS at a multiplicity of infection (MOI) of
2 for 45 to 60 min. Back-plating of inocula was performed to conﬁrm that all groups within an
experiment received the same starting number of bacteria. To measure bacterial killing by macrophages,
RAW 264.7 cells (American Type Culture Collection) were used and maintained in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin (Gibco)
at 37°C in a humidiﬁed incubator with 5% CO2. Brieﬂy, 1 105 RAW cells were seeded onto 13-mm
coverslips in 24-well plates and allowed to adhere overnight. Nonadherent cells were removed with
Hanks’ balanced salt solution (HBSS), and bacteria were added at an MOI of 5. Plates were centrifuged
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at 500  g and incubated at 37°C for 1 h. To enumerate total viable bacteria, 0.03% Triton X-100 was
added, and serial dilutions were plated. Percent elimination was calculated as [(CFUtime zero  CFUﬁnal)/
CFUtime zero]  100. To enumerate viable intracellular bacteria, cells were washed twice with HBSS after
1 h of incubation with bacteria, treated with 100 g/ml gentamicin (Sigma-Aldrich) for 30 min to kill
extracellular bacteria, rinsed twice with HBSS, and incubated with 50 g/ml gentamicin (time zero). After
0, 0.5, 1, and 3 h of incubation, cells were washed twice with HBSS and lysed with 0.3% Triton X-100, and
serial dilutions were plated for determination of CFU. In some experiments, bacteria were cultured (8 to
12 h) in the presence of the following reagents (all reviewed in reference 10) prior to inoculation of
leukocytes to manipulate bacterial levels of H2S: the slow-release H2S donor GYY4137 [morpholin-4-ium
4 methoxyphenyl(morpholino) phosphinodithioate] (0 to 1 mM; Sigma-Aldrich), the 3-MST inhibitor
2-[(4-hydroxy-6-methylpyrimidin-2-yl) sulfanyl]-1-(naphthalen-1-yl)ethan-1-one (0 to 10 M; Molport),
the CSE inhibitor D-L-propargylglycine (PAG) (0 to 30 mM; Sigma), or the CBS inhibitor amino-oxyacetic
acid (AOAA) (0 to 1 mM; Sigma).
(ii) In vivo. To measure bacterial clearance in vivo, mice were injected i.p. with 1 108 CFU E. coli
or 5 108 CFU S. aureus, and tissues were harvested 12 to 16 h later. To measure bacterial growth and
spread within burn wounds, 1 106 CFU S. aureus were injected under the upper half of the burn wound,
and the lower half of the wound was harvested 24 h later. Inocula were back-plated to conﬁrm doses.
Tissues were homogenized in sterile saline, and serial dilutions were plated on agar. Data for all in vivo
inoculation experiments shown are representative of results from 2 to 4 independently performed
experiments. To assess systemic inﬂammation in response to infection, blood was collected when tissues
were harvested for cultures, and IL-6 was measured by an enzyme-linked immunosorbent assay (ELISA)
(Invitrogen, ThermoFisher).
Bacterial H2S production. Lead acetate was used to detect and compare H2S production by bacteria
under different conditions, as described previously (3), with some modiﬁcations. Brieﬂy, equal numbers
of bacteria were cultured in 12-well plates at 37°C at 140 rpm overnight. The lid covering the culture
plate had ﬁlter paper (Bio-Rad), saturated with 2% lead acetate (Sigma-Aldrich), afﬁxed to the inside,
above, but not in contact with, the bacterial cultures. H2S reaction with lead acetate produces a brown
lead sulﬁde stain that is visible on the ﬁlter paper (3).
Bacterial 3MST activity. Bacterial 3MST gene (sseA) (NCBI accession number NC_000913.3) was
cloned and expressed in an E. coli vector system (pET43.1a) and puriﬁed (GenScript Inc., Piscataway, NJ,
USA). The effect of the 3-MST inhibitor on the activity of the bacterial enzyme was determined as
previously described (27), with modiﬁcations. Brieﬂy, the inhibitor was added to assay buffer to yield ﬁnal
concentrations of 1 to 10M in a total assay mixture volume of 200l. The assay solution contained Tris HCl
(50mM; pH 8.0), bacterial full-length 3MST (sseA) (50 ng/well), the 3-MST substrate 3-mercaptopyruvate
(100M ﬁnal concentration), glutathione (2 M ﬁnal concentration), and the H2S-speciﬁc ﬂuorescent
probe 7-azido-4-methylcoumarin (AzMc) (10 M ﬁnal concentration). The 96-well plates were incubated
at 37°C for 2 h, and the increase in the AzMc ﬂuorescence in each well was read at 450 nm (excitation
wavelength [ex] of 365 nm).
Statistical analysis. Data are presented as means  standard errors of the means (SEM) and were
analyzed using GraphPad Prism 7.0 for Windows. Multiple groups were compared by one-way analysis
of variance (ANOVA) followed by Tukey’s multiple-comparison test, and two groups were compared by
unpaired Student’s t test. When unequal variances were detected by an F-test, data were log transformed
for analyses. A P value of 0.05 was considered statistically signiﬁcant.
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